302 related articles for article (PubMed ID: 17100636)
1. Glycolipids as immune modulatory tools.
Lalazar G; Preston S; Zigmond E; Ben Yáacov A; Ilan Y
Mini Rev Med Chem; 2006 Nov; 6(11):1249-53. PubMed ID: 17100636
[TBL] [Abstract][Full Text] [Related]
2. Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis.
El Haj M; Ben Ya'acov A; Lalazar G; Ilan Y
World J Gastroenterol; 2007 Nov; 13(44):5799-804. PubMed ID: 17990345
[TBL] [Abstract][Full Text] [Related]
3. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
4. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
5. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells.
Wu D; Xing GW; Poles MA; Horowitz A; Kinjo Y; Sullivan B; Bodmer-Narkevitch V; Plettenburg O; Kronenberg M; Tsuji M; Ho DD; Wong CH
Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1351-6. PubMed ID: 15665086
[TBL] [Abstract][Full Text] [Related]
6. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
[TBL] [Abstract][Full Text] [Related]
7. NKT cell responses to glycolipid activation.
Tefit JN; Davies G; Serra V
Methods Mol Biol; 2010; 626():149-67. PubMed ID: 20099127
[TBL] [Abstract][Full Text] [Related]
8. Regulation of immune responses by CD1d-restricted natural killer T cells.
Van Kaer L
Immunol Res; 2004; 30(2):139-53. PubMed ID: 15477656
[TBL] [Abstract][Full Text] [Related]
9. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
10. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
[TBL] [Abstract][Full Text] [Related]
11. Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease.
Maricic I; Girardi E; Zajonc DM; Kumar V
J Immunol; 2014 Nov; 193(9):4580-9. PubMed ID: 25261475
[TBL] [Abstract][Full Text] [Related]
12. Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.
Godó M; Sessler T; Hamar P
Curr Med Chem; 2008; 15(18):1778-87. PubMed ID: 18691038
[TBL] [Abstract][Full Text] [Related]
13. The adaptor protein AP-3 is required for CD1d-mediated antigen presentation of glycosphingolipids and development of Valpha14i NKT cells.
Elewaut D; Lawton AP; Nagarajan NA; Maverakis E; Khurana A; Honing S; Benedict CA; Sercarz E; Bakke O; Kronenberg M; Prigozy TI
J Exp Med; 2003 Oct; 198(8):1133-46. PubMed ID: 14557411
[TBL] [Abstract][Full Text] [Related]
14. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.
Miyamoto K; Miyake S; Yamamura T
Nature; 2001 Oct; 413(6855):531-4. PubMed ID: 11586362
[TBL] [Abstract][Full Text] [Related]
15. Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes.
Arora P; Kharkwal SS; Ng TW; Kunnath-Velayudhan S; Saini NK; Johndrow CT; Chang YT; Besra GS; Porcelli SA
Chem Phys Lipids; 2015 Oct; 191():75-83. PubMed ID: 26306469
[TBL] [Abstract][Full Text] [Related]
16. Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers.
Devera TS; Shah HB; Lang GA; Lang ML
Eur J Immunol; 2008 Apr; 38(4):1001-11. PubMed ID: 18350547
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
18. beta-Glycosphingolipids as immune modulators.
Adar T; Ilan Y
J Immunotoxicol; 2008 Apr; 5(2):209-20. PubMed ID: 18569392
[TBL] [Abstract][Full Text] [Related]
19. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
Chang YJ; Huang JR; Tsai YC; Hung JT; Wu D; Fujio M; Wong CH; Yu AL
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10299-304. PubMed ID: 17566107
[TBL] [Abstract][Full Text] [Related]
20. "Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes".
Arora P; Kharkwal SS; Ng TW; Kunnath-Velayudhan S; Saini NK; Johndrow CT; Chang YT; Besra GS; Porcelli SA
Chem Phys Lipids; 2016 Jan; 194():49-57. PubMed ID: 26496152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
